Back to top
more

ANI Pharmaceuticals (ANIP)

(Delayed Data from NSDQ)

$59.20 USD

59.20
312,253

+0.25 (0.42%)

Updated Aug 14, 2024 04:00 PM ET

After-Market: $59.32 +0.12 (0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ANI Pharmaceuticals (ANIP) Stock Moves -0.14%: What You Should Know

by Zacks Equity Research

The latest trading day saw ANI Pharmaceuticals (ANIP) settling at $57.31, representing a -0.14% change from its previous close.

ANI Pharmaceuticals (ANIP) Stock Moves -0.48%: What You Should Know

by Zacks Equity Research

In the most recent trading session, ANI Pharmaceuticals (ANIP) closed at $57.66, indicating a -0.48% shift from the previous trading day.

ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

The latest trading day saw ANI Pharmaceuticals (ANIP) settling at $58.39, representing a -0.41% change from its previous close.

(ANIP) Advances While Market Declines: Some Information for Investors

by Zacks Equity Research

In the most recent trading session, ANI Pharmaceuticals (ANIP) closed at $58.63, indicating a +1.98% shift from the previous trading day.

ANI Pharmaceuticals (ANIP) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

ANI Pharmaceuticals (ANIP) closed at $58.06 in the latest trading session, marking a -1.41% move from the prior day.

Mirati (MRTX) Soars 12.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Mirati (MRTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

ANI Pharmaceuticals (ANIP) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

ANI Pharmaceuticals (ANIP) closed the most recent trading day at $59.33, moving -1.98% from the previous trading session.

ANI Pharmaceuticals (ANIP) Stock Moves -0.9%: What You Should Know

by Zacks Equity Research

ANI Pharmaceuticals (ANIP) closed at $60.53 in the latest trading session, marking a -0.9% move from the prior day.

Elutias (ELUT) Up on Sale of Orthobiologics Business for $35M

by Zacks Equity Research

Elutias (ELUT) gains on divestiture of Orthobiologics business unit for $35 million to Berkeley Biologics LLC, a wholly-owned subsidiary of GNI Group Ltd.

PTC Therapeutics (PTCT) Down on Negative CHMP Opinion for DMD Drug

by Zacks Equity Research

PTC Therapeutics (PTCT) plunges on negative opinion from the Committee for Medicinal Products for Human Use for conditional marketing and full marketing authorization of Translarna (ataluren) to treat nonsense mutation Duchenne muscular dystrophy.

ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $63.61, marking a +1.26% move from the previous day.

UnitedHealth Group (UNH) Wins Medicaid Deal to Help Serve Texas

by Zacks Equity Research

UnitedHealth Group (UNH) unit has been awarded a contract by the Texas Health and Human Services Commission to better cater to the statewide Medicaid members.

Here's Why You Should Add ANI Pharmaceuticals (ANIP) to Your Portfolio

by Zacks Equity Research

ANI Pharmaceuticals (ANIP), a top-ranked stock, has a diverse portfolio of rare disease and generic medicines. Its Purified Cortrophin Gel is witnessing incremental sales in recent quarters.

ANI (ANIP) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, ANI (ANIP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Lisata (LSTA) Up on Positive Updates for Pancreatic Cancer Study

by Zacks Equity Research

Lisata's (LSTA) shares gain on a favorable outcome in interim futility analysis of its lead candidate, LSTA1, for pancreatic cancer.

Palisade (PALI) In-Licenses Rights for IBD Candidate, Stock Up

by Zacks Equity Research

Palisade (PALI) gains on entering into global licensing deal with Giiant Pharma to develop gastrointestinal therapies.

Ensign Group (ENSG) Pursues Facility Buyouts in South Carolina

by Zacks Equity Research

Ensign Group (ENSG) acquires two skilled nursing facilities in South Carolina to offer enhanced healthcare services to the state's residents.

Insmed (INSM) Up on Positive Data From MAC Lung Disease Study

by Zacks Equity Research

Insmed's (INSM) shares rise on positive data from the late-stage ARISE study evaluating Arikayce for newly infected lung disease caused by MAC.

InflaRx (IFRX) Skyrockets 110% in Six Months: Here's Why

by Zacks Equity Research

Shares of InflaRx (IFRX) show an upward trajectory after it obtained authorization for its first-ever marketed drug, which is approved for the treatment of critically ill COVID-19 patients.

Sage Therapeutics (SAGE) Plunges 46% in a Month: Here's Why

by Zacks Equity Research

The plunge in Sage's (SAGE) shares comes after the FDA declined to approve Zurzuvae in major depressive disorder indication, citing management to conduct more clinical studies.

Ekta Bagri headshot

5 Biotech Stocks to Buy as New Drug Approvals Drive Industry Prospects

by Ekta Bagri

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position EXEL, DVAX, ACLX, ANIP and VNDA well amid volatility.

Acer (ACER) to Get Acquired by Zevra for $91M, Stock Up

by Zacks Equity Research

Acer (ACER) surges as Zevra Therapeutics offers to acquire it for approximately $91 million.

Humana (HUM) to Provide In-home Care With Primary Care Anywhere

by Zacks Equity Research

Humana (HUM) enhances its CenterWell brand with the launch of Primary Care Anywhere.

Outlook's (OTLK) Shares Decline on CRL for Wet AMD Candidate

by Zacks Equity Research

Outlook's (OTLK) shares decline as it receives a complete response letter for Lytenava (ONS-5010), treating wet age-related macular degeneration.

Zai Lab (ZLAB) Up on Breakthrough Therapy Tag for Oncology Drug

by Zacks Equity Research

Zai Lab (ZLAB) gains on receiving Breakthrough Therapy designation for repotrectinib from the Center for Drug Evaluation of the National Medical Products Administration in China.